MDACC Study No:2009-0432 ( NCT No: NCT01039844)
Title:Phase I Study of Weekly LOC-paclitaxel Injection
Principal Investigator:Rodabe N. Amaria
Treatment Agent:LOC-paclitaxel
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of LOC-paclitaxel when given to patients with metastatic melanoma. The safety
of this drug and if it can control the disease is also being studied.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I
Treatment Agents:LOC-paclitaxel
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Luitpold Pharmaceutical, Inc.
Return Visit:Every 6 weeks.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Rodabe N. Amaria
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults